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Introduction
Immunotherapy has obtained a prominent role in the field of oncology and has proven valuable in the treatment of different types of tumors. A range of immunotherapies are under development, varying from chimeric antigen receptors (CARs) 1 , expanding tumor infiltrating lymphocytes (TILs) 2, 3 and TCR transduced effector cells 4, 5 . Various studies successfully make use of TCR-engineered T-cells to enhance patients adaptive immune responses against malignancies, demonstrating potent anti-tumor reactivity [6] [7] [8] [9] .
No matter how promising therapies using TCR-engineered T-cells may be, they come with side effects and risks. T-cells are naturally checked for recognition of self-peptides in the context of self-HLA and deleted in the thymus if this recognition is too strong, in a process called negative selection 10 . This selection process is absent or non-optimal when TCRs are derived from donors with mismatched HLA-typing, when they are isolated from humanized mouse models expressing only one HLA molecule and no human proteins, or when TCRs are structurally altered for affinity enhancement 11, 12 .
Affinity enhancement of TCRs can result in both on-and off-target toxicity 13 . Recent examples of clinically tested TCRs directed against MAGE-A3 and MART-1 demonstrated severe toxicities 12, [14] [15] [16] [17] . In the clinical trial testing a modified anti-MAGE-A3 TCR, derived from immunization of HLA-A*02:01 transgenic mice, 2 out of 9 cancer patients developed fatal ontarget neurological toxicity, due to recognition of a peptide derived from the same gene-family which is expressed in the brain 15 . In another trial, where an affinity enhanced anti-MAGE-A3 TCR was tested in myeloma and melanoma patients, 2 patients died due to off-target toxicity caused by recognition of a completely different peptide, resulting in severe myocardial damage 12, 17 . These clinical cases show how difficult it is to predict the exact specificity and the resulting effects of TCRs that did not undergo optimal thymic selection. It is crucial to develop strategies to extensively validate the exact specificity of TCRs, particularly since TCR-engineered T-cells are highly sensitive 14, 18 .
In this study, we aimed to develop a reliable screening pipeline for early detection of off-target toxicity due to the cross-reactivity of TCRs directed against unrelated peptides. In previous work, we have focused on the identification of therapeutic TCRs directed against hematopoietic restricted minor histocompatibility antigens (MiHA) for the treatment of hematological malignancies. The HLA-A*02:01 restricted HA-2 peptide YIGEVLVSV is a well-known example of such a MiHA 19, 20 . In recent experiments we isolated a HA-2 specific T-cell clone, 7B5, using an in vitro HLA-mismatched setting. We validated its specificity for the HA-2 antigen in hematopoietic cell subsets. However, we found unexpected off-target recognition of human fibroblasts not expressing the HA-2 antigen, raising the questions what triggered this activation and what method is suitable to examine this. Thus, we investigated the off-target cross-reactive potential of this high avidity T-cell clone using different screening methods and characterized its fine specificity.
Currently, an amino acid scanning approach is the recommended method 21 , which we compared to screening with a 9-mer combinatorial peptide library (CPL) 22 . To validate recognition of predicted cross-reactive target peptides by the 7B5 T-cell clone, as discovered by the different screening approaches, we then screened the 7B5 T-cell clone against several non-hematopoietic cell subsets endogenously expressing these peptides. As a control, we used a HA-2 specific Tcell clone, HA2.27, previously isolated from a chronic myeloid leukemia patient that experienced a Graft versus Leukemia (GvL) response after HLA-matched SCT and subsequent donor lymphocyte infusion (DLI) 23 . The patient from whom these clones were isolated did not experience any harmful GvHD 24 and no ex vivo cross-reactivity was discovered.
We show that the amino acid scanning approach alone provided useful information about which amino acid (AA) positions in the peptide are important for TCR recognition, but its ability to elucidate the cross-reactivity profile of the 7B5 TCR was limited. Instead, we were able to detect off-target reactivity directed against a peptide derived from CDH13 using a CPL scanning approach. This was confirmed with CDH13 transduced HA-2 neg EBV-LCLs and the potential in vivo consequences were deduced by screening against a broad range of different cell subsets.
Results

Identification of a HA-2 specific T-cell clone from the allogeneic TCR repertoire
T-cell clones from an HLA-A*02:01 neg individual were isolated using pMHC-tetramers composed of the HA-2 peptide bound to HLA-A*02:01. pMHC-tetramer pos cells were first enriched by magnetic-activated cell sorting (MACS) followed by single-cell sorting of pMHCtetramer pos CD8 pos T-cells. T-cell clones were selected that demonstrated reactivity against T2 cells loaded with the HA-2 peptide but not against unloaded T2 cells. Among these T-cell clones, clone 7B5 demonstrated the highest functional sensitivity when stimulated with titrated amounts of HA-2 peptide. This reactivity was comparable to the patient derived control clone HA2.27, that was isolated from a beneficial GVL response after allogeneic stem cell transplantation (SCT) and subsequent DLI ( Figure 1A) .
Specific binding to the APC-labeled HA-2 pMHC-tetramer was validated for both T-cell clones.
Both the 7B5 T-cell clone and the HA2.27 T-cell clone showed specific staining with the APClabeled HA-2 pMHC-tetramer with similar intensity ( Figure 1B) .
Expression of the MYO1G gene, encoding for the MiHA HA-2, is restricted to hematopoietic tissues 20 . We confirmed this restricted expression in an in-house generated microarray gene expression database ( Supplementary Figure 1) 25 . To investigate whether T-cell clone 7B5 was able to selectively recognize cell subsets expressing HA-2 we tested the HA-2 reactive T-cell clones against different hematopoietic cell subsets, starting with SNP-genotyped EBV-LCLs that were either positive or negative for the MiHA HA-2. Robust recognition of HLA-A*02:01 pos HA-2 pos EBV-LCLs, but not HLA-A*02:01 pos HA-2 neg or HLA-A*02:01 neg EBV-LCLs was detected, which was comparable to the HA2.27 T-cell clone (Figure 2A ). In addition, the antitumor reactivity of T-cell clone 7B5 was tested against different HLA-A*02:01 pos primary AML samples either positive or negative for the MiHA HA-2. HLA-A*02:01 pos fibroblasts and HLA-A*02:01 pos keratinocytes were included as HA-2 neg controls. HA-2 pos AML samples were similarly recognized by both the HA2.27 T-cell clone and the 7B5 T-cell clone, whereas the HA-2 neg AML sample was not ( Figure 2B ). However, the HLA-A*02:01 pos HA-2 neg fibroblasts and keratinocytes that were not recognized by the HA2.27 T-cell clone as expected, were efficiently recognized by the 7B5 T-cell clone ( Figure 2B ).
All these results indicate that the 7B5 T-cell clone is a high avidity T-cell clone, capable of targeting HA-2 expressing hematopoietic cell subsets in the context of HLA-A*02:01.
Unexpectedly, the 7B5 T-cell clone recognized HLA-A*02:01 pos HA-2 neg human fibroblasts and keratinocytes as well.
Analysis of off-target cross-reactivity of the 7B5 T-cell clone
We showed that the 7B5 T-cell clone and the HA2.27 T-cell clone have a similar functional sensitivity for HA-2, but the 7B5 T-cell clone demonstrated cross-reactivity against HA-2 neg fibroblasts and keratinocytes. In order to assess what causes this off-target recognition of fibroblasts and keratinocytes we used an alanine scanning approach. Both HA-2 reactive clones were tested against the immunogenic HA-2 sequence (YIGEVLVSV), the naturally occurring non-immunogenic counterpart (YIGEVLVSM), and newly synthesized HA-2 peptides in which every AA is sequentially replaced by an alanine (A). In Table 1 the different peptides are summarized. According to NetMHC4.0 none of the alanine substitutions interfere with HLA-A*02:01 binding to a relevant extent. Both HA-2 T-cell clones were incubated overnight with peptide-pulsed T2 cells at different concentrations (8 nM, 40 nM and 200 nM), and IFN-y production was measured. When alanine substitution resulted in a substantial decrease in IFN-y production compared to the immunogenic HA-2 sequence, this position was considered essential.
The results, depicted in Figure 3A -C, demonstrate that for T-cell clone 7B5 positions 2, 3, 4, 5, 6 and 7 were important for HA-2 specific recognition. This recognition pattern was slightly different from the HA-2.27 clone, since for this clone positions 1, 2, 3, 4, and 6 were important for HA-2 specific recognition.
For the 7B5 T-cell clone an in silico search was carried out to identify protein sequences that contain the motif X-I-G-E-V-L-V-X-X. We searched for human self-protein derived peptide sequences with this motif using the ScanProsite webtool. Besides the HA-2 peptide, this search resulted in only one other peptide sequence PIGEVLVSS derived from the human gene KLF6.
However, this KLF6 derived sequence was not predicted to bind HLA-A*02:01 according to NetMHC4.0, thus we concluded that there was a low risk of cross-reactivity, based on this amino acid scanning approach.
Next we performed a 9-mer combinatorial peptide library (CPL) scan. This CPL is composed of 180 different 9-mer peptide mixtures. In every peptide mixture one AA position has a fixed Lamino acid residue, but all other positions are degenerate enabling incorporation of any 1 of 19 natural L-amino acids in all remaining 8 positions (cysteine is excluded). The 7B5 T-cell clone was incubated overnight with T2 cells pulsed with the 180 different peptide mixtures and IFN-y production was measured. Results are depicted in a heatmap (Figure 4 ). Using the WSBC PI CPL webtool, we conducted a 9-mer CPL-driven search of the human self-protein database to produce a list of the top 100 peptide sequences ranked in order of likelihood of recognition (Supplementary Table 1 ). After removing duplicate sequences a list of 42 peptide sequences remained and further refined on the basis of whether they were predicted to bind HLA-A*02:01 using NetMHC4.0. This resulted in a final list of 10 peptide sequences which were subsequently synthesized ( Table 2 ). The ability of the T-cell clones 7B5 and HA2.27 to recognize these candidate peptides was determined by measuring the IFN-y production after stimulation with T2 cells loaded with titrated concentrations of these peptides. Only one peptide, the CDH13 derived peptide (p01) SVGSVLLTV, was recognized with a similar sensitivity as the HA-2 peptide (p02) ( Figure 5A ). The patient derived HA2.27 control clone did not recognize any other peptide but HA-2 ( Figure 5B ).
In order to confirm processing and presentation of the CDH13 derived peptide in HLA-A*02:01, we transduced CDH13 into two different HLA-A*02:01 pos HA-2 neg EBV-LCLs (IZA and HRK).
Recognition of the transduced and untransduced EBV-LCLs was evaluated by IFN-y ELISA.
The 7B5 T-cell clone did not recognize untransduced HLA-A*02:01 pos HA-2 neg EBV-LCLs, similar to the HA2.27 T-cell clone, but CDH13 transduced HLA-A*02:01 pos HA-2 neg EBV-LCLs were highly recognized by the 7B5 T-cell clone, whereas the HA2.27 T-cell clone was not able to recognize these transduced EBV-LCLs ( Figure 5C ). These results demonstrate that T-cell clone 7B5 is cross-reactive against the CDH13 derived peptide.
Cross-reactivity directed against CDH13
We showed that T-cell clone 7B5 is cross-reactive towards a CDH13 derived peptide which is presented by HLA-A*02:01. Next, we wanted to investigate the possible implications of this cross-reactivity in vivo. According to our gene expression microarray database 25 , the CDH13 gene is expressed by a wide variety of healthy non-hematopoietic cell subsets, e.g. fibroblasts, keratinocytes, proximal tubular epithelial cells and melanoma cell line FM6 ( Supplementary   Figure 2) . We tested the 7B5 T-cell clone against keratinocytes and fibroblasts derived from HLA-A*02:01 pos donors, either untreated or pretreated with IFN-y for 2 days to upregulate HLA expression, and HLA-A*02:01 pos proximal tubular epithelial cells and melanoma cell line FM6.
All cell-subsets were recognized by the 7B5 T-cell clone, but not by the HA2.27 T-cell clone ( Figure 6 ). To confirm that only HLA-A*02:01 restricted epitopes were recognized, we included HLA-A*02:01 neg fibroblasts, either untreated or pretreated with IFN-y for 2 days. The HLA-A*02:01 neg fibroblasts were unable to activate the 7B5 T-cell clone ( Figure 6 ).
All these results demonstrate that the 7B5 T-cell clone can activate in response to both the HA-2 antigen and the CDH13 derived peptide SVGSVLLTV, causing cross-reactivity restricted to HLA-A*02:01 pos tissues.
Discussion
In this study, we detected off-target reactivity of the 7B5 TCR directed against a peptide derived from the gene CDH13 using a CPL scanning approach, which was confirmed by the ability of the 7B5 T-cell clone to recognize CDH13 transduced HA-2 neg EBV-LCLs and several cell subsets endogenously expressing CDH13. We show that the standard alanine scanning approach alone provided useful information about which AA positions in the peptide are important for TCR recognition, but its ability to elucidate cross-reactivity for the 7B5 TCR was limited.
The 7B5 T-cell clone was isolated from a HLA-A*02:01 negative donor, thus due to the HLA- The results of the alanine scanning approach suggested a low risk for broad cross-reactivity of the 7B5 T-cell clone, since exchanging the AAs for an alanine at positions 2, 3, 4, 5, 6 or 7 resulted in complete loss of peptide recognition. These results do not exclude the possibility of cross-reactivity towards other specific peptides, but it dismisses the risk of a highly promiscuous TCR. A search for specific human self-protein derived peptides with the motif X-I-G-E-V-L-V-X-X did not yield any potential off-target toxicity candidates. However, when we used the 9-mer CPL scan data to conduct a CPL-driven search of the human self-protein database, we found cross-reactivity directed against a peptide derived from the gene CDH13. This was confirmed by the ability of the 7B5 T-cell clone to recognize HA-2 neg EBV-LCLs transduced with the CDH13 gene and a range of tissues that endogenously express CDH13 including fibroblasts, keratinocytes and proximal tubular epithelial cells (PTEC).
All these results demonstrate that the 7B5 T-cell clone can activate in response to healthy HLA-A*02:01 pos tissues such as fibroblasts, which is likely to have severe clinical consequences if this TCR was engineered into T-cells for adoptive therapy in patients. Therefore, we conclude that thorough validation of the specificity and characterization of cross-reactivity by combining several screening techniques should be a strict prerequisite for TCRs to be tested prior to their use in the clinic.
The alanine scanning approach was insufficient for detecting potentially dangerous crossreactivities, whereas a CPL-driven search of the human self-protein database enabled the identification of a potentially dangerous reactivity directed towards a human self-protein derived epitope. In the alanine scanning approach only one AA is replaced at a time and the AAs are only replaced with a single AA (alanine), no other AAs with different properties. So it is no surprise that cross-reactivity against a peptide that differs from the MiHA peptide HA-2 in 5 AA positions, cannot be discovered using this assay. Because the 9-mer CPL fixes only one AA at one position per peptide mixture, all possible sequences (except those with more than one cysteine) are represented in the assay and cross-reactive peptides that differ substantially from the immunogenic target peptide can be identified. The downside of this approach is that every mixture consists of many peptides, lowering the concentration per unique peptide and increasing the competition for HLA-binding within every mixture. These factors might influence the results and could explain why for some T-cell clones that we tested with the 9-mer CPL, a sufficient peptide recognition signature could not be determined (data not shown). Also, the 9-mer CPLdriven search of the human self-protein database produces such a great number of potential candidates that a selection strategy is needed to keep further screening experiments manageable, risking unwanted exclusion of the target peptides you're searching for.
Although the 7B5 T-cell clone, which is derived from a HLA-mismatched setting, showed a potentially dangerous cross-reactivity, this does not mean that all TCRs from an allogeneic setting are of lesser clinical interest compared to clones derived from HLA-matched settings, e.g. the patient derived T-cell clone HA2.27. All TCRs have an intrinsic cross-reactive capacity 26 , which is necessary to cover all naturally occurring antigens that may be encountered 27 . Thus, the relevant question is not whether a TCR is cross-reactive, but how to predict the clinical consequences of this cross-reactivity 28 . Therefore, thorough screening for off-target toxicity must be included in the preclinical phases, to determine whether a TCR is safe for clinical application via adoptive transfer of TCR-engineered T-cells. To further reduce potential risks, the use of a so called 'suicide switch' could also be considered 29 , which enables immediate elimination of the transfused T-cells upon signs of toxicity.
In summary, we demonstrate that a standard alanine scanning approach provided useful information about which positions in the peptide sequence are important for TCR recognition, but it did not predict off-target reactivity of the 7B5 TCR. However, we were able to detect offtarget reactivity directed against a peptide derived from CDH13 using a CPL-driven search of the human self-protein database, which was confirmed using CDH13 transduced HA-2 neg EBV-LCLs and screening against several different cell subsets which endogenously express CDH13.
This example demonstrates the advantage and need of combining several screening techniques to characterize the cross-reactivity and specificity of TCRs.
Materials and Methods
Culture conditions and cells
All studies using human material were approved by the Leiden University 
Isolation of the HA-2 reactive T-cell clone 7B5
To isolate HA-2 reactive T-cell clones, 500x10 6 PBMCs from an HLA-A*02:01 neg healthy donor were incubated with PE-labeled pMHC-tetramers, composed of HA-2 9-mer peptide 
FACS analysis
FACS acquisition was performed on a LSRII (BD Biosciences) and was analyzed using Diva Software (BD Biosciences). T-cell clones were analyzed for binding to the HA-2 specific APClabeled pMHC-tetramer, an irrelevant PE-labeled pMHC-tetramer and an Alexa700-conjugated antibody against CD8 (Invitrogen/Calteg). 10,000 T-cells were first incubated with 2 µg/ml pMHC-tetramers for 15 min at 37°C and washed, before anti-CD8 antibodies were added and incubated for an additional 15 min at 4°C.
Functional analysis
For analysis of IFN-γ production, 5000 T-cells were cocultured with 30,000 target cells or T2 cells loaded with peptides in 384 well plates. Peptide loading was performed by incubating T2 cells for 30 minutes at 37°C and 5% CO 2 . T-cells were washed twice before use. After overnight incubation, supernatants were harvested, and the concentration of IFN-γ was measured by ELISA (Sanquin Reagents).
To assess the peptide recognition signature we used a previously described 9-mer CPL scan 22 , consisting of 180 different peptide mixtures. In each peptide mixture all peptides have one fixed L-amino acid (AA) residue at one AA position, but all other positions are degenerate, enabling incorporation of any 1 of 19 natural L-amino acids in all remaining 8 positions (cysteine is excluded in non-fixed positions). For this assay, we pulsed 20,000 T2 cells with each of the 180 different peptide mixtures at a concentration of 100 µM for two hours at 37°C and 5% CO 2 in 40 µl T-cell medium (IMDM supplemented with 100 IU/ml IL-2, 5% fetal bovine serum, 5% human serum, 2 mM L-glutamine and 1% penicillin/streptomycin). After peptide loading, 4000 T-cells in 20 µl T-cell medium were added per well. After overnight incubation, supernatants were harvested and IFN-y production was measured by ELISA (Sanquin Reagents).
Analysis of the peptide recognition signature
To analyze the data from the 9-mer CPL scan, we used the WSBC PI CPL webtool 30 that applies a mathematical strategy to match the peptide recognition signature 31 with the human proteome to predict the most likely human self-protein derived peptide sequences that might be recognized by the tested TCR 26 . We examined 100 peptides with the best log likelihood scores and removed duplicate sequences. The 10 peptide sequences that were predicted to bind HLA-A*02:01, according to NetMHC4.0, were synthesized.
Gene transduction
The CDH13 gene was cloned into the modified MP71-retroviral backbone, together with the truncated nerve growth factor-receptor (NGF-R, also known as CD271). The constructs were transfected into Phoenix-A cells using helper vector M57 and Fugene HD reagent (Roche). Virus supernatant was harvested after 48 and 72 hours and stored at -80°C.
For transduction of EBV-LCLs, 24-well non tissue-culture plates were coated with 30 mg/ml retronectin (Takara) for 2 hours at room temperature and blocked with 2% human serum albumin (Sanquin Reagents) for 30 minutes. Viral supernatant was thawed, then 500 µl per well was added to the 24-well plate and spun down at 2000 G for 20 minutes at 4°C. 100,000 EBV-LCLs per well were added in 500 µl fresh IMDM supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin and incubated overnight at 37°C and 5% CO 2 . 
